Taysha Gene Therapies Inc. (TSHA) NASDAQ

$2.66 (0.28) (-9.52%)

Market Cap: $549.83M

As of 04/15/24 03:59 PM EDT. Market closed.

(TSHA)

Taysha Gene Therapies Inc. (TSHA)
NASDAQ

$2.66
(0.28) (-9.52%)

Market Cap: $549.83M

As of 04/15/24 03:59 PM EDT. Market closed.

Add to Portfolio

taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency ... read more

taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Full Time Employees
96
Address
.
PRICE CHART FOR TAYSHA GENE THERAPIES INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$2.90
Previous Close
$2.94
Days Range
$2.93 - $3.27
52 week range
$0.50 - $3.89
Volume
2,029,333
Avg. Volume (30 days)
4,099,204
Market Cap
$549.83M
Dividend Yield
-
P/E
(4.93)
Shares Outstanding
187,018,275
Open
$2.90
Previous Close
$2.94
Days Range
$2.93 - $3.27
52 week range
$0.50 - $3.89
Volume
2,029,333
Avg. Volume (30 days)
4,099,204
Market Cap
$549.83M
Dividend Yield
-
P/E
(4.93)
Shares Outstanding
187,018,275
FINANCIAL STATEMENTS FOR TAYSHA GENE THERAPIES INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR TAYSHA GENE THERAPIES INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Alam KamranCHIEF FINANCIAL OFFICERFeb 02, 2024 Option Exercise$1.511,2881,945840,937Feb 06, 2024, 04:42 PM
Manning Paul B10% OwnerNov 17, 2023 Buy$1.63100,000163,00016,566,667Nov 20, 2023, 07:35 AM
Alam KamranChief Financial OfficerAug 24, 2023 Sale$2.3333,00076,890258,042Aug 25, 2023, 04:30 PM
Manning Paul B10% OwnerAug 16, 2023 Buy$0.9016,466,66714,820,00016,466,667Aug 16, 2023, 08:57 PM
Stalfort John A IIIDirectorAug 16, 2023 Buy$0.90388,889350,000999,381Aug 16, 2023, 08:53 PM
Stalfort John A IIIDirectorAug 16, 2023 Buy$0.90388,889350,000884,290Aug 16, 2023, 08:53 PM
Nolan Sean P.Chief Executive OfficerAug 16, 2023 Buy$0.90444,444400,0001,535,545Aug 16, 2023, 08:52 PM
Donenberg Phillip B.DirectorAug 16, 2023 Buy$0.90111,111100,000114,111Aug 16, 2023, 08:51 PM
Session R.A. II10% OwnerJul 12, 2023 Sale$0.7180,52857,0308,877,091Jul 14, 2023, 04:00 PM
Session R.A. II10% OwnerJul 13, 2023 Sale$0.705,3443,7418,871,747Jul 14, 2023, 04:00 PM
Session R.A. II10% OwnerJun 23, 2023 Sale$0.7018,10012,7358,957,619Jun 26, 2023, 04:46 PM
Session R.A. II10% OwnerJun 22, 2023 Sale$0.7010,5087,3848,975,719Jun 26, 2023, 04:46 PM
Session R.A. II10% OwnerJun 21, 2023 Sale$0.70138,96297,6358,986,227Jun 22, 2023, 04:00 PM
Session R.A. II10% OwnerJun 20, 2023 Sale$0.71295,653210,2099,125,189Jun 22, 2023, 04:00 PM
Nagendran SukumarPresident and Head of R&DMay 16, 2023 Buy$0.685,0003,40034,226May 18, 2023, 04:44 PM
Manning Paul BDirectorOct 31, 2022 Buy$2.001,500,0003,000,0001,642,202Nov 02, 2022, 04:09 PM
Alam KamranChief Financial OfficerAug 23, 2022 Sale$3.473,32511,538266,121Aug 24, 2022, 04:47 PM
Alam KamranChief Financial OfficerAug 22, 2022 Sale$3.509,71734,010269,446Aug 22, 2022, 08:05 PM
Alam KamranChief Financial OfficerAug 19, 2022 Sale$3.7511,48243,058279,163Aug 22, 2022, 08:05 PM
Alam KamranChief Financial OfficerAug 18, 2022 Sale$3.877,47628,932290,645Aug 22, 2022, 08:05 PM
PRASAD SUYASHCMO and Head of R&DJul 06, 2022 Sale$3.798,95633,943530,589Jul 07, 2022, 04:30 PM
PRASAD SUYASHCMO and Head of R&DJul 05, 2022 Sale$3.513,90513,707539,545Jul 07, 2022, 04:30 PM
PRASAD SUYASHCMO and Head of R&DJul 01, 2022 Sale$3.5323,92384,448543,450Jul 01, 2022, 06:55 PM
PRASAD SUYASHCMO and Head of R&DJun 30, 2022 Sale$3.7213,89251,678567,373Jul 01, 2022, 06:55 PM
PRASAD SUYASHCMO and Head of R&DJun 29, 2022 Sale$3.8112,32446,954581,265Jul 01, 2022, 06:55 PM
Manning Paul BDirectorFeb 02, 2022 Buy$7.7758,000450,66092,202Feb 04, 2022, 08:28 AM
Manning Paul BDirectorFeb 03, 2022 Buy$7.8426,602208,5602,091,704Feb 04, 2022, 08:28 AM
Manning Paul BDirectorFeb 03, 2022 Buy$7.8450,000392,000142,202Feb 04, 2022, 08:28 AM
Manning Paul BDirectorFeb 02, 2022 Buy$7.7767,000520,5902,065,102Feb 04, 2022, 08:28 AM
Nagendran SukumarDirectorFeb 02, 2022 Buy$8.0110,00080,10029,226Feb 03, 2022, 09:21 AM
Donenberg Phillip B.DirectorFeb 02, 2022 Buy$7.783,00023,3403,000Feb 03, 2022, 07:04 AM
Session R.A. IIPresident and CEONov 23, 2021 Buy$12.4442,518529,1029,190,920Dec 08, 2021, 04:05 PM
Manning Paul BDirectorNov 24, 2021 Buy$13.192,20229,04434,202Nov 29, 2021, 05:01 PM
Manning Paul BDirectorNov 23, 2021 Buy$12.5420,000250,80032,000Nov 24, 2021, 07:58 AM
Alam KamranChief Financial OfficerAug 19, 2021 Sale$16.479,967164,175310,574Aug 20, 2021, 05:52 PM
Alam KamranChief Financial OfficerAug 18, 2021 Sale$17.3511,193194,199319,928Aug 20, 2021, 05:52 PM
Alam KamranChief Financial OfficerAug 20, 2021 Sale$16.7811,840198,649300,215Aug 20, 2021, 05:52 PM
PRASAD SUYASHCMO and Head of R&DJul 01, 2021 Sale$21.1219,706416,191593,589Jul 01, 2021, 06:32 PM
PRASAD SUYASHCMO and Head of R&DJun 30, 2021 Sale$21.7920,076437,494619,997Jul 01, 2021, 06:32 PM
PRASAD SUYASHCMO and Head of R&DJun 29, 2021 Sale$23.8239,218934,251637,533Jul 01, 2021, 06:32 PM
Manning Paul BDirectorMay 14, 2021 Buy$20.9812,000251,76012,000May 17, 2021, 07:48 AM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Alam KamranCHIEF FINANCIAL OFFICER02/02/20241,945
Manning Paul B10% Owner11/17/2023163,000
Alam KamranChief Financial Officer08/24/202376,890
Manning Paul B10% Owner08/16/202314,820,000
Stalfort John A IIIDirector08/16/2023350,000
Stalfort John A IIIDirector08/16/2023350,000
Nolan Sean P.Chief Executive Officer08/16/2023400,000
Donenberg Phillip B.Director08/16/2023100,000
Session R.A. II10% Owner07/12/202357,030
Session R.A. II10% Owner07/13/20233,741
Session R.A. II10% Owner06/23/202312,735
Session R.A. II10% Owner06/22/20237,384
Session R.A. II10% Owner06/21/202397,635
Session R.A. II10% Owner06/20/2023210,209
Nagendran SukumarPresident and Head of R&D05/16/20233,400
Manning Paul BDirector10/31/20223,000,000
Alam KamranChief Financial Officer08/23/202211,538
Alam KamranChief Financial Officer08/22/202234,010
Alam KamranChief Financial Officer08/19/202243,058
Alam KamranChief Financial Officer08/18/202228,932
PRASAD SUYASHCMO and Head of R&D07/06/202233,943
PRASAD SUYASHCMO and Head of R&D07/05/202213,707
PRASAD SUYASHCMO and Head of R&D07/01/202284,448
PRASAD SUYASHCMO and Head of R&D06/30/202251,678
PRASAD SUYASHCMO and Head of R&D06/29/202246,954
Manning Paul BDirector02/02/2022450,660
Manning Paul BDirector02/03/2022208,560
Manning Paul BDirector02/03/2022392,000
Manning Paul BDirector02/02/2022520,590
Nagendran SukumarDirector02/02/202280,100
Donenberg Phillip B.Director02/02/202223,340
Session R.A. IIPresident and CEO11/23/2021529,102
Manning Paul BDirector11/24/202129,044
Manning Paul BDirector11/23/2021250,800
Alam KamranChief Financial Officer08/19/2021164,175
Alam KamranChief Financial Officer08/18/2021194,199
Alam KamranChief Financial Officer08/20/2021198,649
PRASAD SUYASHCMO and Head of R&D07/01/2021416,191
PRASAD SUYASHCMO and Head of R&D06/30/2021437,494
PRASAD SUYASHCMO and Head of R&D06/29/2021934,251
Manning Paul BDirector05/14/2021251,760
Load More Insider Transactions
FUNDS WITH A POSITION IN TAYSHA GENE THERAPIES INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
RA CAPITAL MANAGEMENT, L.P.18,472,5030.51%No changeOther
BAKER BROS. ADVISORS LP4,004,7560.08%59.89%Other
TYBOURNE CAPITAL MANAGEMENT (HK) LTD3,700,0000.98%146.67%Growth, Growth At A Reasonable Price
BLACKROCK INC.2,699,2380.00012%260.83%Other
RENAISSANCE TECHNOLOGIES LLC1,097,4000.00301%83.51%Other
GEODE CAPITAL MANAGEMENT, LLC985,4210.00018%113.45%Other
PALO ALTO INVESTORS LP529,8610.08%NewOther
ADAGE CAPITAL PARTNERS GP, L.L.C.420,0000.00154%-72%Other
CHANGE IN SHARES OUTSTANDING FOR TAYSHA GENE THERAPIES INC
STOCK BUYBACKS FOR TAYSHA GENE THERAPIES INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
-7.62%
1Q

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
-7.62%
1Q
BUYBACK ANNOUNCEMENT(S) FOR TAYSHA GENE THERAPIES INC
LOADING...